Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032107 · ClinicalTrials.gov registry record · Phase 1
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03032107: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT03032107 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03032107, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: * Pembrolizumab * Trastuzumab emtansine (also called T-DM1)
Primary Outcome
The number and type of DLTs as defined in the protocol that occur during the first 21 days of treatment and all maximum grade of all treatment-related adverse events using CTCAE v4.0 will be used to identify a safe and tolerable dose
Interventions
- DRUG Pembrolizumab
- DRUG T-DM1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-02-17 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 1 |
What the finished NCT03032107 record still lists
NCT03032107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03032107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03032107 about?
NCT03032107 is a clinical study titled "A Study Of Pembrolizumab In Combination With Trastuzumab-DM1". This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: * Pembrolizumab * Trastuzumab emtansine (also called T-DM1)
What is the current status of trial NCT03032107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-02-17. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT03032107?
The interventions under investigation include: Pembrolizumab (DRUG), T-DM1 (DRUG).
Who is sponsoring clinical trial NCT03032107?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03032107's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI